[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE68916777D1 - Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis. - Google Patents

Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.

Info

Publication number
DE68916777D1
DE68916777D1 DE68916777T DE68916777T DE68916777D1 DE 68916777 D1 DE68916777 D1 DE 68916777D1 DE 68916777 T DE68916777 T DE 68916777T DE 68916777 T DE68916777 T DE 68916777T DE 68916777 D1 DE68916777 D1 DE 68916777D1
Authority
DE
Germany
Prior art keywords
psoriasis
treatment
tnf
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68916777T
Other languages
English (en)
Other versions
DE68916777T2 (de
Inventor
Hiroshi Ishimaru
Kazuyoshi Hori
Patrick Joseph Creaven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Publication of DE68916777D1 publication Critical patent/DE68916777D1/de
Application granted granted Critical
Publication of DE68916777T2 publication Critical patent/DE68916777T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE68916777T 1988-12-27 1989-12-04 Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis. Expired - Lifetime DE68916777T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29049788A 1988-12-27 1988-12-27

Publications (2)

Publication Number Publication Date
DE68916777D1 true DE68916777D1 (de) 1994-08-18
DE68916777T2 DE68916777T2 (de) 1995-03-16

Family

ID=23116275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68916777T Expired - Lifetime DE68916777T2 (de) 1988-12-27 1989-12-04 Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.

Country Status (7)

Country Link
EP (1) EP0377823B1 (de)
JP (1) JPH02209812A (de)
AT (1) ATE108331T1 (de)
AU (1) AU633037B2 (de)
CA (1) CA2003981C (de)
DE (1) DE68916777T2 (de)
DK (1) DK658889A (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659235A1 (fr) * 1990-03-09 1991-09-13 Asahi Chemical Ind Application du facteur tumoral de necrose au traitement des troubles de demyelinisation, de l'uveite ou des troubles de l'hote qui a recu une greffe.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN106729633A (zh) * 2017-03-03 2017-05-31 上海唯科生物制药有限公司 一种肿瘤坏死因子直肠给药制剂及其制备方法
EP4263607A1 (de) * 2020-12-16 2023-10-25 Molecular Partners AG Neue prodrugs mit langsamer freisetzung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS61292727A (ja) * 1985-06-20 1986-12-23 Nec Corp キ−ボ−ド
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells

Also Published As

Publication number Publication date
JPH02209812A (ja) 1990-08-21
EP0377823A3 (de) 1991-09-11
DK658889D0 (da) 1989-12-22
JPH0565492B2 (de) 1993-09-17
EP0377823A2 (de) 1990-07-18
ATE108331T1 (de) 1994-07-15
EP0377823B1 (de) 1994-07-13
DE68916777T2 (de) 1995-03-16
DK658889A (da) 1990-06-28
CA2003981A1 (en) 1990-06-27
AU633037B2 (en) 1993-01-21
AU4685389A (en) 1990-07-05
CA2003981C (en) 2000-06-13

Similar Documents

Publication Publication Date Title
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
AU4312285A (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
BG50159A3 (en) Method for preparing derivatives of piranobenzadiasole
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
ATE118221T1 (de) Verwendung von tumornekrosefaktor.
HU9202229D0 (en) Method for manufacturing new pharmaceutical preparatives containing 2-oxo-benzimidaazoline-1-carboxylic acid derivatives
AU617277B2 (en) 2-alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia
DE69516602D1 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
AU2716592A (en) Treatment of anxiety in benzodiazepine-withdrawn patients
ATE145133T1 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)- ester-verbindungen zur herstellung eines arzneimittels zur behandlung der neuromuskuläre inkontinenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation